BusinessVoyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXMay 9, 2017, 8:14 PM UTC
BusinessVoyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXMay 9, 2017, 8:14 PM UTC
BusinessVoyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXMay 9, 2017, 8:14 PM UTC
BusinessVoyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXMay 9, 2017, 8:14 PM UTC
BusinessVoyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s DiseaseBy Nasdaq OMXApr 25, 2017, 11:02 AM UTC
BusinessVoyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s DiseaseBy Nasdaq OMXDec 7, 2016, 9:05 PM UTC
BusinessVoyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of TechnologyBy Nasdaq OMXSep 15, 2016, 11:05 AM UTC
BusinessVoyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s DiseaseBy Nasdaq OMXSep 12, 2016, 11:05 AM UTC
